Tag: CAPTEM
Phase II Clinical Trial Recruiting Carcinoid and Related Neuroendocrine Tumor Patients
July 21, 2011
Participants are being recruited for a Phase II clinical study of capecitabine and temozolomide (CAPTEM) for neuroendocrine cancer patients with progressive, differentiated, metastatic neuroendocrine tumors (NETs). Patients with carcinoid,…
READ MORE